Go CAR-Ting and Beyond for Kids: State of the Art of Pediatric Cell-Based Therapies

Moderator(s)

• 

  Shaun Jackson, MD, PhD

  Seattle Children's Research Institute
  Seattle, Washington, United States

  Disclosure(s): Merck/MSD: Consultant (Ongoing)
• HW

  Holly Wobma, MD;PhD

  Boston Children's Hospital
  Boston, MA, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

Session Coordinator(s)

• SS

  Susan Shenoi, MS;MBBS;RhMSUS

  Seattle Children's Hospital and Research Center
  Mercer Island, WA, United States

  Disclosure(s): AbbVie/Abbott: Consultant (Terminated); cabaletta: Consultant (Ongoing); sobi: Consultant (Ongoing)
• EO

  Ekemini Ogbu, MD;MSc

  Cincinnati Children's Hospital Medical Center
  Cincinnati, OH, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose

This session will explore the emergence and potential impact of Chimeric Antigen Receptor (CAR) T-cell therapies in pediatric rheumatic diseases. It will provide a comprehensive overview of recent advancements in the field, with a focus on CAR T-cell therapy research in childhood-onset systemic lupus erythematosus and juvenile dermatomyositis. The session will also address the ethical and practical challenges associated with conducting cell-based therapy research in rare pediatric rheumatic diseases and discuss future opportunities for innovation and development in this area.

Presentations:

• 9:00 AM - 10:00 AM Central Time

  State of the Art: Pediatric Cell-Based Therapies
  

  Speaker: Georg Schett, MD – Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany